Business Context and Reporting Period
Company: Sanofi-Synthelabo (Foreign Private Issuer)
Filing Type: Form 6-K
Reporting Period: First half of 2002 (January 1, 2002 – June 30, 2002)
Release Date: August 30, 2002 (Filed September 4, 2002)
Context: The Group reported strong growth driven by the full consolidation of the Lorex Pharmaceuticals joint venture in the U.S., the launch of new products (Arixtra, Eloxatin, Elitek), and robust performance of top-selling drugs (Plavix, Ambien, Aprovel). The company also listed on the NYSE as of July 1, 2002.
Key Financial Metrics
| Metric (in millions of EUR) | H1 2001 | H1 2002 | Change |
|---|---|---|---|
| Consolidated Sales | 3,159 | 3,680 | +16.5% (Reported) / +14.8% (Comparable) |
| Gross Profit | 2,496 | 2,974 | +19.2% |
| Gross Margin | 79.0% | 80.8% | +1.8 pts |
| Operating Profit | 975 | 1,233 | +26.5% |
| Net Profit Attributable to Group | 671 | 830 | +23.7% |
| Net Profit (Adj.)* | 643 | 828 | +28.8% |
| Earnings Per Share (Adj.)* | 0.88 | 1.13 | +28.4% |
| Operating Cash Flow | 784 | 390 | -50.3% |
| Cash Position (End of Period) | 2,763 | 2,392 | -13.4% |
*Adjusted for exceptional items and goodwill amortization.
Material Changes vs. Prior Period
- Sales Growth: Reported sales grew 16.5%, while comparable sales grew 14.8%. The 1.7% variance is attributed to structural changes: 100% consolidation of Lorex Pharmaceuticals (vs. 47% previously), 51% proportionate consolidation of the Fujisawa joint venture in Japan, and the deconsolidation of Ela Medical.
- Profitability: Operating profit rose 26.5% to €1,233 million. This was driven by the full consolidation of Lorex profits and strong sales of the top 15 products (+23%), partially offset by inventory reductions of Plavix by partner Bristol-Myers Squibb in the U.S.
- Expenses: R&D expenses increased 18.1% to €587 million (16% of sales) due to major Phase III trials (rimonabant, dronedarone, tirapazamine) and new collaborations. Selling and general expenses rose 10.4% to €1,239 million.
- Taxation: Income taxes decreased 16.3% to €313 million due to a reassessment of the worldwide tax position, full consolidation of Lorex, and French tax cuts, lowering the effective tax rate.
- Geographic Mix: The U.S. share of operating profit increased from 38% to 43%, while Europe's share decreased from 47% to 44%.
Guidance, Outlook, and Risks
Outlook
Management confirmed prospects for growth of over 25% in net profit attributable to the Group (before exceptional items and goodwill amortization) for the full year 2002, barring major adverse events.
Recent Developments
- Approvals: FDA approvals received for Elitek (hyperuricemia), Eligard (prostate cancer), and Eloxatin (colorectal cancer). CPMP positive opinion for Plavix in acute coronary syndrome.
- Acquisitions: Signed agreement to acquire pharmaceutical assets of Korean company Kunwha; acquired 6 million treasury shares (0.8% of capital) for €361 million.
- Patents: Obtained patent protection for the crystalline polymorphic form 2 of clopidogrel bisulfate (Plavix) in the U.S. and Europe.
Risks and Contingencies
- Forward-Looking Statements: Results depend on the ability to expand profitably in the U.S., success of R&D programs, and protection of intellectual property.
- Regulatory/Reimbursement: Risks associated with healthcare cost reimbursement and pricing reforms, particularly in the U.S. and France.
- Patent Challenges: Generic challenges to Plavix in the U.S. and patent expiration for Ambien in October 2006 (mitigated by development of modified-release formulations).
Investor Verification Checklist
- Structural Adjustments: Verify the impact of the 100% consolidation of Lorex Pharmaceuticals on reported vs. comparable growth figures.
- Cash Flow Divergence: Investigate the significant drop in operating cash flow (from €784m to €390m) despite rising profits, driven by a €697m increase in working capital needs and €1,026m in capital expenditures.
- Plavix Inventory: Assess the long-term impact of the Bristol-Myers Squibb inventory reduction program on U.S. sales stability.
- R&D Pipeline: Monitor the progress of Phase III trials for rimonabant (smoking cessation), dronedarone (arrhythmia), and idraparinux (anticoagulant) as key future growth drivers.
- Patent Expirations: Review the timeline and mitigation strategies for Ambien patent expiration in 2006 and potential generic entry for Plavix.